drugset
drugset / Trial / NCT01285609

Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin

NCT01285609 ↗

Phase 3 Completed 1289 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to determine whether Ipilimumab plus Paclitaxel and Carboplatin will extend the lives of patients with squamous only non small cell lung cancer more than placebo plus Paclitaxel and Carboplatin.

Timeline

Start
2011-01-16
Primary completion
2015-06-09
Completion
2017-08-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipilimumab Monoclonal antibody 10 mg/kg Intravenous
Background Carboplatin Small molecule — Intravenous
Background Paclitaxel Small molecule 175 mg/m2 Intravenous

Indications

non-small cell squamous lung carcinoma